Literature DB >> 31603586

Long-term safety and efficacy of 24-hour levodopa-carbidopa intestinal gel in Parkinson's disease.

Hugo Morales-Briceño1,2, Neil Mahant1, Ainhi D Ha1, Florence C F Chang1,2, Samuel D Kim1, Jane Griffith1, David Tsui1, Donna Galea1, Victor S C Fung1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31603586     DOI： 10.1002/mds.27883

Source DB:  PubMed          Journal:  Mov Disord        ISSN： 0885-3185            Impact factor:   10.338


× No keyword cloud information.
  4 in total

1.  Levodopa/Carbidopa Intestinal Gel Long-Term Outcome in Parkinson's Disease: Focus on Dyskinesia.

Authors:  Margherita Fabbri; Maurizio Zibetti; Giovanna Calandra-Buonaura; Manuela Contin; Luisa Sambati; Susan Mohamed; Alberto Romagnolo; Paola Berchialla; Gabriele Imbalzano; Giulia Giannini; Mario G Rizzone; Carlo Alberto Artusi; Pietro Cortelli; Leonardo Lopiano
Journal:  Mov Disord Clin Pract       Date:  2020-09-18

Review 2.  Intrajejunal Infusion of Levodopa/Carbidopa for Advanced Parkinson's Disease: A Systematic Review.

Authors:  Taiji Tsunemi; Genko Oyama; Shinji Saiki; Taku Hatano; Jiro Fukae; Yasushi Shimo; Nobutaka Hattori
Journal:  Mov Disord       Date:  2021-04-25       Impact factor: 9.698

Review 3.  24-Hour Levodopa-Carbidopa Intestinal Gel: Clinical Experience and Practical Recommendations.

Authors:  Sandeep Thakkar; Victor S C Fung; Aristide Merola; Meredith Rollins; Michael J Soileau; Norbert Kovács
Journal:  CNS Drugs       Date:  2021-02-13       Impact factor: 5.749

4.  Management Challenges of Severe, Complex Dyskinesia. Data from a Large Cohort of Patients Treated with Levodopa-Carbidopa Intestinal Gel for Advanced Parkinson's Disease.

Authors:  József Attila Szász; Viorelia Adelina Constantin; Károly Orbán-Kis; Ligia Ariana Bancu; Marius Ciorba; István Mihály; Előd Ernő Nagy; Róbert Máté Szász; Krisztina Kelemen; Mihaela Adriana Simu; Szabolcs Szatmári
Journal:  Brain Sci       Date:  2021-06-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.